Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses

Drug and Alcohol Dependence

Volumn 69, Issue 2, 2003, Pages 205-211

  Shinderman, Marc ^a   Maxwell, Sarz ^a   Brawand Amey, Marlyse ^b   Golay, Kerry Powell ^b   Baumann, Pierre ^b   Eap, Chin B ^b  

^a Center for Addictive Problems   (United States)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Cytochrome P4503A4; Metabolism; Methadone; Midazolam

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A4; METHADONE; MIDAZOLAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; METHADONE TREATMENT; PRIORITY JOURNAL;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; STEREOISOMERISM;

EID: 0037370274     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(02)00320-4     Document Type: Article

References (36)

1. Altice F.L., Friedland G.H., Cooney E.L. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 13:1999;957-962.
2. Bart P.-A., Rizzardi G.P., Gallant S., Powell Golay K., Baumann P., Pantaleo G., Eap C.B. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther. Drug Monit. 23:2001;553-555.
3. Begré S., von Bardeleben U., Ladewig D., Jaquet-Rochat S., Cosendai-Savary L., Powell Golay K., Kosel M., Baumann P., Eap C.B. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J. Clin. Psychopharmacol. 22:2002;211-215.
4. Borg L., Kreek M.J. Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-1-positive and AIDS patients. Curr. Opin. Psychiatry. 8:1995;199-202.
5. Bouër R., Barthe L., Philibert C., Tournaire C., Woodley J., Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam. Clin. Pharmacol. 13:1999;494-500.
6. Boulton D.W., Arnaud P., DeVane C.L. A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. Br. J. Clin. Pharmacol. 51:2001;350-354.
7. Boulton D.W., Arnaud P., DeVane C.L. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin. Pharmacol. Ther. 70:2001;48-57.
8. Carrillo J.A., Ramos S.I., Agúndez J.A.G., Martinez C., Benitez J. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther. Drug Monit. 20:1998;319-324.
9. Charlier C., Dessalles M.C., Plomteux G. Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient. Ther. Drug Monit. 23:2001;1-3.
10. de Wildt S.N., Kearns G.L., Leeder J.S., van den Anker J.N. Cytochrome P450 3A - ontogeny and drug disposition. Clin. Pharmacokinet. 37:1999;485-505.
11. Eap C.B., Finkbeiner T., Gastpar M., Scherbaum N., Powell K., Baumann P. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur. J. Clin. Pharmacol. 50:1996;385-389.
12. Eap C.B., Bertschy G., Powell K., Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J. Clin. Psychopharmacol. 17:1997;113-117.
13. Eap C.B., Bourquin M., Martin J.L., Spagnoli J., Livoti S., Powell K., Baumann P., Déglon J.J. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend. 61:2000;47-54.
14. Eap C.B., Broly F., Mino A., Hämmig R., Déglon J.J., Uehlinger C., Meili D., Chevalley A.F., Bertschy G., Zullino D., Kosel M., Preisig M., Baumann P. Cytochrome P4502D6 genotype and methadone steady-state concentrations. J. Clin. Psychopharmacol. 21:2000;229-234.
15. Foster D.J.R., Somogyi A.A., Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Bri. J. Clin. Pharmacol. 47:1999;403-412.
16. Herrlin K., Segerdahl M., Gustafsson L.L., Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet. 356:2000;2069-2070.
17. Hunt C.M., Watkins P.B., Saenger P., Stave G.M., Barlascini N., Watlington C.O., Wright J.T., Guzelian P.S. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin. Pharmacol. Ther. 51:1992;18-23.
18. Iribarne C., Berthou F., Baird S., Dréano Y., Picart D., Bail J.P., Beaune P., Ménez J.F. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9:1996;365-373.
19. Iribarne C., Picart D., Dréano Y., Berthou F. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam. Clin. Pharmacol. 12:1998;194-199.
20. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., Roden M.M., Belas F., Chaudhary A.K., Roden D.M., Wood A.J.J., Wilkinson G.R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16:1999;408-414.
21. Leavitt S.B., Shinderman M., Maxwell S., Eap C.B., Paris P. When 'enough' is not enough: new perspectives on optimal methadone maintenance dose. Mt. Sinai J. Med. 67:2000;404-411.
22. Liu S.J., Wang R.I.H. Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome. Am. J. Psychiatry. 141:1984;1287-1288.
23. Marzolini C., Troillet N., Telenti A., Baumann P., Decosterd L.A., Eap C.B. Efavirenz decreases methadone blood concentrations. AIDS. 14:2000;1291-1292.
24. Maxwell S., Shinderman M. Optimizing response to methadone maintenance treatment: use of higher dose of methadone. J. Psychoactive Drugs. 31:1999;95-102.
25. Moody D.E., Alburges M.E., Parker R.J., Collins J.M., Strong J.M. The involvement of cytochrome P450 3A4 in the N-demethylation of L-a-acetylmethadol (LAAM), norlaam, and methadone. Drug Metab. Dispos. 25:1997;1347-1353.
26. Otero M.J., Fuertes A., Sánchez R., Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS. 13:1999;1004-1005.
27. Rostami-Hodjegan A., Wolff K., Hay A.W.M., Raistrick D., Calvert R., Tucker G.T. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br. J. Clin. Pharmacol. 48:1999;43-52.
28. Rostami-Hodjegan, A., Foster, D.J.R., Charlier, C., Somogyi, A.A., Eap, C.B., Bochner, F., Tucker, G.T., 2001. A meta-analysis of the dose-concentration relationship for methadone and a nomogram to assess compliance and metabolic variability. J. Psychopharmacol. (15), A35 (abstract).
29. Störmer E., Perloff M.D., von Moltke L.L., Greenblatt D.J. Methadone inhibits rhodamine123 transport in caco-2 cells. Drug Metab. Dispos. 29:2001;954-956.
30. Streetman D.S., Bertino J.S. Jr, Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 10:2000;187-216.
31. Takano M., Hasegawa R., Fukuda T., Yumoto R., Nagai J., Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midalozam and ketoconazole in caco-2 cells. Eur. J. Pharmacol. 358:1998;289-294.
32. Thompson S.J., Koszdin K., Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 92:2000;1399.
33. Thummel K.E., Shen D.D., Podoll T.D., Kunze K.L., Trager W.F., Bacchi C.E., Marsh C.L., Vicar J.P., Barr C.L., Perkins J.D. Use of midazolam as a human cytochrome P450 3A probe: II. characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. 271:1994;557-566.
34. Thummel K.E., Shen D.D., Podoll T.D., Kunze K.L., Trager W.F., Hartwell P.S., Raisys V.A., Marsh C.L., McVicar J.P., Barr D.M., Perkins J.D., Carithers R.L. Jr. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271:1994;549-556.
35. Villeneuve J.-P., L'Ecuyer L., De Maeght S., Bannon P. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe. Clin. Pharmacol. Ther. 67:2000;242-248.
36. Yue, Q.Y., Svensson, J.O., Bertilsson, L., Säwe, J., 1995. Racemic methadone kinetics in relation to the debrisoquine hydroxylation polymorphism in man. Therapie 88 (abstract).